ESAO 2015 in Leuven, Belgium


yESAO 2014


41st Annual Congress of the ESAO in Rome

Prof. Celestino Pio Lombardi, Gemelli Polyclinics, Catholic University of the Sacred Heart in Rome, and Prof. Gerardo Catapano organize the 41st Annual Congress of the European Society for Artificial Organs (ESAO) in Rome, Italy.

The 41st ESAO Congress will be focused on “Patient happiness: the Holy Grail of organ substitution”, and will be held on September 17-20, 2014 at the Giovanni XXIII congress center located inside the Gemelli Polyclinics in Rome, Italy. The meeting is expected to attract aprox. 600 participants with both clinical and technical expertise from all over the world.
The objective of the Congress is to bring together scientists with different backgrounds working at the development, optimization and translation to the clinics of treatments of organ deficits based on the use of artificial, bioartificial, and cell-based organs or prostheses, and to discuss the importance of technical, psychological and ethical issues to the happiness of patients with serious tissue or organ deficits so as to re-define the design criteria of devices and treatments.
Please, check the ESAO website ( for the actual availability of the Congress website (

ESAO 2013 in Glasgow

The XXXX ESAO Congress took place in Glasgow, September 11th - 14th, 2013. This year we had three oral presentations focussing on our latest results in decellularization and recellularization of the liver. Ben Strücker presented our latest results on „Improved rat liver decellularization by arterial perfusion under oscillating surrounding pressure“. Antje Butter and Karl Hillebrandt gave two oral presentations during the yESAO Rapid Fire Session on „Proprietary rat liver decellularization device utilizing oscillating surrounding pressure to improve micro perfusion within the organ“ and Pig liver decellularisation through portal vein and hepatic artery perfusion under oscillating surrounding pressure“.
Furthermore, Karl Hillebrandt received the „2. Prize for the best Poster“!

IEEE Engineering in Medicine and Biology Society

The 35th Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC’13) will take place 3-7 July 2013, at the Osaka International Convention Center, in Osaka, Japan.
The conference will cover diverse topics such as biomedical engineering, healthcare technologies, and medical and clinical applications.
The ESAO will be represented via a minisymposium entitled "Artificial Organs for Metabolic Support. The most Challenging Problems". Jan Wojcicki will give a presentation on "Artificial Organs for Metabolic Support: The Most Challenging Problems of Artificial Pancreas", Bernd Stegmayr on "Artificial Organs for Metabolic Support: The Most Challenging Problems in Severe Kidney Injury When Dialysis Is Necessary" and Igor Sauer on "Artificial Organs for Metabolic Support: The Most Challenging Problems of Liver Support".

XXXX ESAO Congress in Glasgow

The European Society for Artificial Organs (ESAO) invites you to the XXXX ESAO Congress of the society to be held in Glasgow (Scotland, UK), September 11th-14th 2013.The motto of the ESAO congress will be 'lab to patient - from concept to treatment.

Latest information is available via !

Presentations at ESAO 2012 in Rostock, Germany

This year members of the team gave the following presentations:

“Liver: Current regenerative strategies and future solutions for the liver" (N. Raschzok, oral presentation)

"Neohybrid liver graft - a novel concept of in vivo tissue-engineering" (S. Rohn, oral presentation)

"Micro RNAs in liver regeneration: the mysterious MIR-352" (L. Lisboa, oral presentation)

"Micron-sized iron oxide particles for detection and loco-regional stimulation of transplanted liver cells" (A. Leder, oral presentation)

"Prospective validation of cross organ serum protein biomarkers – Initial results with CXCL9 and CD44 for diagnosis of acute liver rejection" (K.A. Prabowo, poster presentation)

ESAO 2006 in Umeå, Sweden

An ideal extracorporeal liver support system has to provide the main functions of the liver: detoxification, synthesis and regulation. But do we need such an ideal in all clinical situations and can we afford it? The critical issue of the clinical syndrome in liver failure is the accumulation of toxins not cleared by the failing liver. This understanding led to the development of cell-free artificial liver support systems. This special issue of Therapeutic Apheresis and Dialysis is dedicated to cell-free artificial liver support, intended to give engineering scientists, inventors and clinical investigators an update and a better insight into the development and clinical evaluation of cell-free liver support systems. It gives an update on the status quo, both clinically and technically, of different concepts and discusses the current limitations as well as possible solutions. When compared to the cell-based systems, these devices are characterized by easier logistics, lower costs, and absence of hazards related to the cell source. These might be the reasons for being well ahead of the bioartificial concepts in terms of clinical evaluation and application.
Therapeutic Apheresis and Dialysis, April 2006 - Vol. 10 Issue 2:
S. Mitzner et al.: Albumin Regeneration in Liver Support—Comparison of Different Methods J. Patzer: Principles of Bound Solute Dialysis J. Vienken et al.: How Can Liver Toxins be Removed? Filtration and Adsorption With the Prometheus System K. Rifai et al.: Review Article: Clinical Experience With Prometheus J. Rozga et al.: A Novel Plasma Filtration Therapy for Hepatic Failure: Preclinical Studies S.R. Ash: Sorbent Suspensions vs. Sorbent Columns for Extracorporeal Detoxification in Hepatic Failure D. Falkenhagen: Fluidized Bed Adsorbent Systems for Extracorporeal Liver Support L.J. Li: Artificial Liver Support System in China: A Review Over the Last 30 Years R.A.F.M. Chamuleau: Bioartificial Liver: Its Pros and Cons W. Bernal et al.: Cell-Free Artificial Liver Support: Design of Appropriate Clinical Studies with a guest editorial by I.M. Sauer and U. Baurmeister: Cell-Free Artificial Liver Support.

Presentations at the ESAO 2005

Thema: "Tödliche Verwechselungen (Therapie der Konollenblätterpilvergiftung)"
Dr. J. Schefold, Med. Klinik m.S. Nephrologie u. Int. Intensivmedizin, CVK
PD Dr. T. Berg, Med. Klinik m.S. Hepatologie/Gastroenterologie, CVK
Dr. I.M. Sauer, Chirurgie, CVK
Diskutant: Prof. Dr. Dörken, Med. Klinik m.S. Hämatologie/Onkologie

Dienstag, 23.08.2005, 13.00 Uhr im Kursraum 6, Mittelallee 10, Untergeschoss, der Charité - Campus Virchow. Die Veranstaltung ist zertifiziert und ergibt 1 Weiterbildungpunkt der ÄK.

EPGS: One Day On Acute Liver Failure

Webcasts of selcted presentations (including videos and slides) of 8th meeting of the Catalan Transplant Foundation in Barcelona 2005 are available via the offical webpage. Some talks deal with the "Tratamiento de la insuficiencia hepática aguda".

ESAO 2004: Working Group Liver Support


More than 200 unique visits were registered during the first month. Thanks for all the comments and critics!

ESAO 2007 - One Day on the Liver

Nathanael Raschzok, Haluk Morgül, and Florian Vondran presented their latest results at the XXXIV Congress of ESAO 2007 in Krems, Austria:
  • N. Raschzok, M.H. Morgul, F.W.R. Vondran, R. Schwartlander, I.M. Sauer: The SlideObserver – A new concept for the parallel operation of two SlideReactor bioreactor systems
  • M.H. Morgul, N. Raschzok, R. Schwartlander, F.W.R. Vondran, G. Pless, J. Pinkernelle, U. Teichgraber, I.M. Sauer: Transplantation of primary human hepatocytes – iron oxide labelling for cell detection via MRI
  • F.W.R. Vondran, E. Katenz, R. Schwartlander, M.H. Morgul, N. Raschzok, X. Gong, X. Cheng, P. Neuhaus, I.M. Sauer: Impact of donor liver characteristics on the cell function of primary human hepatocytes

ESAO 2007 - Presentations

During the annual meeting of the ESAO 2007 in Krems Dr. Igor M. Sauer has been elected for the Board of Governors of the European Society for Artificial Organs (ESAO).

ESAO Board of Governors - I.M. Sauer elected

Paul P.C. Poyck from the Department of Surgery (Experimental Surgery) of the Academic Medical Center (AMC), University of Amsterdam, The Netherlands, successfully defended his thesis entitled "Towards application of a human liver cell line for use in the AMC bioartificial liver".
The Berlin group congratulates him and Prof. Chamuleau for his great work! 

ESAO One Day on the Liver 2008 in Geneva


One Day on the Liver 2008 - Programme

The Steering Committee of the Berlin-Brandenburg Center for Regenerative Therapies (BCRT) decided to involve Igor Sauer and his group as an Associated Investigator (AI).
The BCRT is a cooperative research institution of the Charite University Hospital in Berlin and Germany's largest research association, the Helmholtz Association. BCRT also receives generous financial support from the BMBF and the states of Berlin and Brandenburg, as well as from the Technology Foundations in Berlin and Brandenburg, the Future Fund Berlin and from various industry partners. More than 15 regional partners from science and industry are active members of the consortium at the BCRT.


Vom 18. - 20. Juni 2009 findet die Molekulare Bildgebung 2009 (MoBi) in der Charite - Universitätsmedizin Berlin, Campus Virchow-Klinikum statt. Die MoBi ist die jährlich stattfindende Jahrestagung des Interdisziplinären Netzwerkes Molekulare Bildgebung (INMB), das in diesem Jahr von dem Imaging Netzwerk Berlin (INB) in Berlin ausgerichtet wird. Das Programm der Molekularen Bildgebung 2009 verspricht einen interessanten Dialog zwischen jungen und gestandenen Wissenschaftlern aus verschiedenen Disziplinen sowie zwischen Forschung und Industrie. Dabei werden in Schwerpunkt-Sessions unter anderem auch die immer wichtiger werdenden Fragen der Regulation und der klinischen Anwendung molekularer Bildgebungsverfahren thematisiert.
Mehr Informationen via .

ESAO 2009 - Program online

The Editor-in-Chief Paul S. Malchesky of Artificial Organs informed us that the articles "`Blogs` and `Wikis Are Valuable Software Tools for Communication Within Research Groups" and "Isolation of primary human hepatocytes after partial hepatectomy: criteria for identification of the most promising liver specimen" were in the top 25 articles viewed online in 2008 at Blackwell Synergy.

One Day on the Liver 2009

At the XXXVI Annual Meeting of the European Society for Artificial Organs ESAO 2009  in Compiègne/France the following projects have been presented by members of our group:

  • Tracking of transplanted liver cells via clinical 3.0 tesla MRI A. Zielinski, K. Steinz, N. Raschzok, N. Billecke, N. Kammer, M.H. Morgul, M. Adonopulou, S. Schmeisser, J. Pinkernelle, W. Ruedinger, U. Teichgraeber, I.M. Sauer
  • Evaluation of application sites for liver cell transplantation in a large animal model K. Steinz, A. Zielinski, N. Raschzok, N. Billecke, N.N. Kammer, M.H. Morgul, M. Adonopulou, L. Morawietz, W. Rüdinger, I.M. Sauer
  • Methylprednisolone and tacrolimus prevent hypothermia induced endothelial dysfunction - possible use in transplantation surgery K.R.L. Schmitt, A. Diestel, N. Billecke, F. Berger, I.M. Sauer

ESAO 2009 - presentations

In her Berlin studio, Sarah Illenberger created wonderful delicate knit wool organs. Unfortunately al liver is still pending:


Wool organs by visual artist Sarah Illenberger. Photographed by Andreas Achmann for Süddeutsche Zeitung Magazin. 

XXXVII ESAO Congress in Skopje

At the Charité, our scientists and physicians engage in state-of-the-art research, patient care and education. More than half of the German Nobel Prize winners in medicine and physiology come from the Charité, among them Emil von Behring, Robert Koch and Paul Ehrlich. The Charité also has an international reputation for excellence in training. It extends over four campuses with more than 100 clinics and institutes bundled under 17 CharitéCenters. The Charité has a turnover of nearly 1 billion euros per year, and it is one of the largest employers in Berlin with 14,500 employees.
In 2010, the Charité will celebrate its 300-year anniversary and will do everything to make this historical event a memorable one.
Short film covering the Charité - Universitätsmedizin celebrating its 300-year anniversary  (47.91 MB)

Presentations at this year's XXXVII ESAO Congress

Hannelore Ringe published the investigations concerning the applicability, efficacy, and safety of single-pass albumin dialysis in children ("Continuous veno-venous single-pass albumin hemodiafiltration in children with acute liver failure." Pediatr Crit Care Med. 2010 Oct 1. [Epub ahead of print]). Co-authors are Varnholt V, Zimmering M, Luck W, Gratopp A, König K, Reich S, Sauer IM, Gaedicke G, and Querfeld U.
The paper reports on a retrospective data review of uncontrolled clinical data of an university-based pediatric intensive care unit collaborating with a local center for liver transplantation.  Nine children, aged 2 to 15 yrs, who were treated with single-pass albumin dialysis for acute liver failure of various origins under a compassionate-use protocol between 2000 and 2006. All patients met high-urgency liver transplantation criteria. Single-pass albumin dialysis was performed as rescue therapy for children with acute liver failure. The decrease in hepatic encephalopathy (grades 1-4) and the serum levels of bilirubin, bile acids, and ammonium were measured to assess the efficacy of detoxification. As a measure of liver synthesis function, thromboplastin time and fibrinogen were analyzed. The safety of the procedure was assessed by documenting adverse effects on mean arterial blood pressure, platelet count, and clinical course. Seven out of nine patients were bridged successfully to either native organ recovery (n = 1) or liver transplantation (n = 7), one of them twice. Six out of nine patients undergoing single-pass albumin dialysis (ten treatments) survived. In six patients, hepatic encephalopathy could be reduced at least by one degree. Ammonium, bilirubin, and bile acid levels decreased in all patients. One patient had an allergic reaction to albumin. In childhood acute liver failure, treatment with single-pass albumin dialysis was generally well tolerated and seems to be effective in detoxification and in improving blood pressure, thus stabilizing the critical condition of children before liver transplantation and facilitating bridging to liver transplantation. It may be beneficial in avoiding severe neurologic sequelae after acute liver failure and thereby improve survival. Single-pass albumin dialysis is an inexpensive albumin-based detoxification system that is easy to set up and requires little training. Whether and to what extent single-pass albumin dialysis can support children with acute liver failure until native liver recovery remain unclear.